| Acronym | Genos d.o.o. |
| Short description of the institution and main activities | Genos Ltd. is a private research and development organization specializing in glycomics, glycoproteomics, epigenetics, molecular biology, and advanced bioanalytical technologies. Genos combines cutting-edge scientific research with the development of novel analytical methods and technologies and their application in biomedicine, biotechnology, pharmaceuticals, and personalized medicine. Its main research and development activities include high-throughput glycan and glycoprotein analysis, quantitative and site-specific characterization of glycosylation, mass spectrometry, development and validation of analytical methods, DNA methylation and gene expression analysis, development of CRISPR/dCas9 molecular tools, and biostatistical, bioinformatics, and multi-omics data analysis. Genos also develops customized analytical methods tailored to the specific needs of research and industry partners. Genos brings together more than 50 experts and researchers, including 30 PhD holders, and operates approximately 600 m² of specialized laboratory facilities equipped with advanced high-throughput analytical infrastructure, including UPLC and capillary electrophoresis platforms, automated robotic sample-preparation systems, and advanced mass spectrometry instrumentation. This infrastructure enables the organization to conduct large-scale research studies and tens of thousands of specialized analyses annually. The organization has extensive experience in international and national research and innovation projects, as well as in collaboration with leading academic institutions, clinical centers, biotechnology companies, and pharmaceutical companies. Collaboration with external partners includes joint R&D projects, contract research, development and optimization of analytical methods, specialized analytical services, and testing and validation of new technologies. In addition to its research activities, Genos has substantial experience in the creation, protection, management, and commercialization of intellectual property. Research results have been translated into patented technologies, licensing agreements, spinout companies, and innovative products and services. One example is GlycanAge, which originated from Genos research and was commercialized through licensing and a dedicated spinout company. Genos therefore has practical experience across the entire innovation cycle—from scientific discovery and method development to validation, intellectual property protection, commercialization, and international market deployment. Genos is also a NATO DIANA Affiliated Test Centre, making it part of the international DIANA network for the development and testing of advanced technologies. In this role, Genos makes its specialized expertise, laboratory infrastructure, and analytical capabilities available to DIANA innovators for the testing, validation, and further development of technologies at TRL 4 and above, including biotechnology and other technologies with potential dual-use applications. |
| Website | https://genos.hr/home |
| LinkedIn or other profile | https://www.linkedin.com/company/genos-ltd/ |
| Year of establishment | 19 |
| Region | City of Zagreb |
| County | City of Zagreb |
| Municipality/City | Zagreb |
| Address | Borongajska cesta 83H |
| Type of organisation | Other |
| Type of organisation other | Private research organisation |
| Languages of communication | Croatian, English |
| Geographic scope of activities | EU / international |
| General institutional email for collaboration enquiries | Not specified |
| Name | Gordan lauc |
| Position | Board Member |
| glauc@genos.hr | |
| Phone | +385 91 5159 555 |
| Name | Maja Pučić Baković |
| Position | Lead scientist |
| Not specified | |
| Phone | + 385 91 4336 704 |
| Dedicated industry collaboration / technology transfer unit | Yes |
| Services available to external partners | Applied research & development, Testing / measurement / validation, Prototyping / proof of concept, Pilot production / scale-up |
| Models of engagement | Contract research, Joint R&D projects, Consultancy, Co-development / PPP, Internships / staff exchange |
| Pricing / access model | Case-by-case |
| Process for initiating collaboration | Contact Genos with a brief description of your research or technology needs. Our experts will assess the requirements and arrange an online or in-person meeting to discuss the project and propose the most suitable collaboration model, including contract research, analytical services, joint R&D, method development and validation, or technology testing |
| Main research fields and areas of expertise | Genos specializes in glycomics, glycoproteomics, epigenetics, molecular biology, and advanced bioanalytical technologies. Key areas of expertise include high-throughput glycan profiling, quantitative and site-specific glycosylation analysis, mass spectrometry-based glycoproteomics, biomarker discovery and validation, DNA methylation and gene expression analysis, CRISPR/dCas9 technologies, and the development and validation of advanced analytical methods. A particular focus is the discovery and development of glycan-based biomarkers for ageing and age-related conditions, including diabetes, cardiometabolic diseases and menopause. Genos also has strong expertise in biostatistics, bioinformatics and multi-omics data analysis, with applications in personalized medicine, diagnostics, biotechnology and pharmaceutical research. |
| Key equipment, laboratories, or infrastructure available to external partners | Genos operates approximately 600 m² of specialized laboratory facilities at BioCenter Zagreb, equipped for high-throughput glycomics, glycoproteomics and advanced bioanalytical research. Key infrastructure includes seven Waters UPLC systems with fluorescence detection, two Avant 3500 DNA analyzers used for glycan analysis, a Tecan EVO 200 robotic platform for automated sample preparation, and advanced mass spectrometry facilities, including an Orbitrap Exploris 240 coupled to UHPLC and two Waters nano-UPLC systems coupled to Bruker Compact Q-TOF mass spectrometers. The infrastructure supports high-throughput glycan profiling, structural and site-specific glycosylation analysis, glycoproteomics, biomarker research, method development and validation, and large-scale research studies. Genos makes its expertise and infrastructure available to external academic and industry partners through analytical services, contract research, joint R&D projects, and technology testing and validation. |
| Accreditation and certification (if applicable) | ISO 9001 (Quality Management) |
| Technology Readiness Levels typically reached | TRL 1-3 (basic / fundamental research), TRL 4-6 (applied research / prototype), TRL 7-9 (demonstration / near-market / deployment) |
| Computing / digital / AI capabilities (if applicable) | Genos has strong computational capabilities in biostatistics, bioinformatics and the analysis of large-scale glycomics and multi-omics datasets. Expertise includes data processing and quality control, statistical modelling, biomarker discovery and validation, integration of clinical and molecular data, and predictive modelling. Genos also applies machine learning and AI-based approaches to biomarker research, patient stratification and the development of data-driven tools for personalized and preventive medicine. These capabilities complement Genos’ high-throughput laboratory platforms and enable integrated experimental and computational research projects with external partners. |
| Intellectual property approach | Case-by-case |
| Existing licensable technologies or patents | Genos currently has no patents or technologies actively offered for licensing. However, two patented technologies have already been successfully licensed, demonstrating Genos’ experience in technology transfer and commercialization. New technologies and IP are continuously developed through ongoing R&D activities, and potential licensing opportunities can be discussed with interested partners. |
| Possibility of | Establishing a joint laboratory with industry partner |
| Primary sector(s) | Healthcare & medical devices, Biotechnology & pharmaceuticals |
| Main technology domains | Biotechnology & bioengineering |
| Experience with industry partners | EU projects with industry |
| Number of contract research agreements | 5 |
| Number of joint R&D projects | 28 |
| Number of licensing agreements | 1 |
| Total number of industry collaboration contracts | Not specified |
| Total number of employees | 56 |
| Number of experts available for external collaboration | 15 |
| Key skills and disciplines | Genos brings together a highly multidisciplinary team with expertise in glycobiology, glycomics, glycoproteomics, biochemistry, molecular and cell biology, genetics, epigenetics, analytical chemistry, biotechnology, pharmaceutical R&D, biostatistics and bioinformatics. Core expertise includes high-throughput glycan profiling, UPLC- and capillary electrophoresis-based glycomics, mass spectrometry-based glycoproteomics, structural and site-specific glycosylation analysis, with particular expertise in immunoglobulin G (IgG) and plasma protein glycosylation. The team has extensive expertise in investigating the genetic, molecular and epigenetic regulation of protein glycosylation and its role in human physiology, ageing and disease. Particular strengths include biomarker discovery and validation in diabetes and metabolic disorders, cardiometabolic diseases, ageing and menopause, as well as population, clinical and translational glycomics. Additional capabilities include CRISPR/dCas9-based genome and epigenome engineering, targeted regulation of gene expression, molecular cloning, cell culture and cellular models, DNA methylation and gene expression analysis. Genos also has strong capabilities in experimental design, processing and quality control of large-scale omics datasets, advanced statistical modelling, bioinformatics, predictive modelling and multi-omics data integration. The multidisciplinary team combines biomarker discovery with analytical method development and validation, pharmaceutical R&D, diagnostic development, regulatory expertise and translation of research findings toward clinical and commercial applications. This combination of high-throughput laboratory technologies, molecular and cellular biology, advanced data analysis and translational expertise enables Genos to support projects from fundamental research and biomarker discovery through validation and technology development to personalized medicine, diagnostics, biotechnology and pharmaceutical applications. |
| Languages available for collaboration | English |
| Talent support available | Industrial PhD / joint supervision |
| Lifelong learning / professional education | Develop tailor-made / custom programmes for industry |
| Lifelong learning key programmes | Genos does not currently offer formal lifelong learning programmes. However, it provides specialized training, workshops and knowledge transfer in glycomics, glycoproteomics, molecular biology, epigenetics, advanced bioanalytical methods, biostatistics and bioinformatics, tailored to the needs of academic and industry partners. |
| Approximate number of industry participants per year | -1 |
| Target beneficiaries | Not specified |
| Types of support offered | Not specified |
| Approximate number of companies supported per year | Not specified |
| Programme formats | Not specified |
| Typical programme duration | Not specified |
| Sector focus | Not specified |
| Links to financing | Not specified |
| Participation in international or EU projects | Genos has extensive experience in international and EU-funded research and innovation projects and is currently participating in 27 ongoing EU and Horizon Europe projects. These projects involve collaboration with leading European academic institutions, clinical centres, biotechnology companies and industry partners. Through its international project portfolio, Genos contributes expertise in glycomics, glycoproteomics, biomarker discovery and validation, personalized and precision medicine, ageing, metabolic and cardiometabolic diseases, immunology, biotechnology and data-driven health research. Its roles include research leadership, development and validation of analytical methods and biomarkers, high-throughput omics analyses, biostatistics and bioinformatics, technology development, and translation of research results towards clinical and commercial applications. Genos also has extensive previous experience in FP7, Horizon 2020 and Horizon Europe programmes, demonstrating a strong track record in managing and implementing complex international collaborative R&D projects. |
| Membership in networks or partnerships | Genos is a NATO DIANA Affiliated Test Centre and part of the international DIANA network supporting the development, testing and validation of emerging and dual-use technologies. Genos is also actively involved in numerous European and international research and innovation networks and partnerships established through FP7, Horizon 2020 and Horizon Europe programmes. At the national level, Genos has played a key role in major collaborative research and innovation initiatives, including the Scientific Centre of Excellence for Personalised Healthcare and the Competence Centre for Molecular Diagnostics (CEKOM). These initiatives bring together research institutions, healthcare organisations and industry partners to advance personalised medicine, molecular diagnostics, biomarker development and the translation of scientific discoveries into innovative products and services. Through these networks and partnerships, Genos maintains long-term collaborations with leading universities, research institutes, clinical centres, biotechnology and pharmaceutical companies in Croatia, across Europe and internationally. Its partnerships span glycomics and glycoproteomics, personalised and preventive medicine, molecular diagnostics, biomarker development, biotechnology, AI-supported healthcare, technology development and knowledge transfer, connecting academic excellence with clinical and industrial applications. |
| Can you support partners in navigating local procedures | Yes |
| Physical space available to external partners | Laboratory / workshop |
